Aller au contenu principal
Accès ouvert déclaré 2026 article

Very low enalapril and enalaprilat exposure via human milk: a case report from the ConcePTION project

0Citations signalées — pas une note de qualité
8Institutions déclarées
5Pays d’affiliation déclarés

Résumé fourni par la source

Introduction Ongoing maternal and clinical hesitancy in breastfeeding-related shared decision-making is driven by limited safety data on maternal pharmacotherapy. Theoretical exposure to maternal enalapril and its active metabolite enalaprilat in breastfed infants has previously been reported in two studies of eight mother-infant pairs. However, actual infant plasma concentrations remain uncharacterized. Methods A 30-year-old white woman started enalapril (5 mg, 1x/day) for IgA nephropathy at 11 weeks postpartum while exclusively breastfeeding. On day 101 postpartum, 25 days after therapy start, she collected six steady-state milk samples over 24 h, along with two maternal and one infant blood sample, used to calculate milk-to-plasma (M/P) ratio and estimated infant exposure. Samples were analyzed using liquid chromatography with tandem mass spectrometry. Maternal and infant health information was concurrently collected via structured questionnaires. Results Low levels of enalapril (0.01–1.22 ng/mL) and enalaprilat (0.32–0.77 ng/mL) were measured in human milk. Using 200 and 150 mL/kg/day milk intake, estimated daily infant dosage was 78.32 ng/kg/day and 58.82 ng/kg for enalapril and 124.45 ng/kg/day and 93.34 ng/kg/day for enalaprilat, corresponding to a relative infant dose (RID) of 0.097% and 0.073% for enalapril. Infant enalapril and enalaprilat plasma concentrations were below the lower limit of quantification. Discussion These data support evidence of minimal transfer of enalapril and enalaprilat into human milk, suggesting low risk to breastfed infants, and may help address uncertainties in current clinical guidelines. This case report provides detailed maternal pharmacokinetic data for both compounds in human milk, alongside estimated infant exposure at 3 months postpartum.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Very low enalapril and enalaprilat exposure via human milk: a case report from the ConcePTION project
Date Crossref
20/01/2026
Éditeur
Frontiers Media SA
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Pregnancy and Medication ImpactPharmacological Effects and Toxicity StudiesDrug Transport and Resistance Mechanisms

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.